Irfan Khan, MD
Ophthalmology · Charlottesville, VANPI 1164714051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 100 payments — averaging $25.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$503
- Alimera Sciences, Inc.$375
- AbbVie$363
- Sun Pharmaceutical Industries Inc.$245
- Regeneron Healthcare Solutions, Inc.$187
- Bausch & Lomb Americas Inc.$133
- plus $696 from 12 others
Across 3 payments — averaging $35,233 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$106K
What the payments were for
- Food & beverage$2,495100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 15 | $503 |
| Alimera Sciences, Inc. | 12 | $375 |
| AbbVie(2 entities) | 18 | $363 |
| Sun Pharmaceutical Industries Inc. | 14 | $245 |
| Regeneron Healthcare Solutions, Inc. | 7 | $187 |
| Bausch & Lomb Americas Inc. | 7 | $133 |
| ANI Pharmaceuticals, Inc. | 6 | $133 |
| Mallinckrodt Hospital Products Inc. | 4 | $117 |
| Genentech, Inc. | 1 | $102 |
| Eyepoint US, Inc. | 4 | $80 |
| Harrow Eye, LLC | 3 | $68 |
| Alcon | 3 | $56 |
| Sandoz | 1 | $32 |
| Astellas Pharma US Inc | 1 | $28 |
| Tarsus Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $21 |
| Bayer | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,501 in reported general payments places this provider in the 70th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $255,960 |
| RestasisCyclosporine | 81 | $62,722 |
| Prednisolone Acetate | 475 | $20,994 |
| MieboPerfluorohexyloctane/Pf | 12 | $15,350 |
| XiidraLifitegrast | 17 | $11,569 |
| LumiganBimatoprost | 28 | $11,562 |
| TyrvayaVarenicline Tartrate | 18 | $11,465 |
| Cyclosporine | 26 | $8,782 |
| RhopressaNetarsudil Mesylate | 13 | $7,227 |
| Difluprednate | 31 | $5,366 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 71 | $3,540 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 93 | $2,041 |
| Timolol Maleate | 56 | $2,016 |
| ValacyclovirValacyclovir Hcl | 37 | $1,532 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 178 | $1,472 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $363 | $74,285109 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $133 | $26,91929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Charlottesville
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
- Albert JunCharlottesville$49K
- Peter NetlandCharlottesville$35K
- James GigantelliCharlottesville$10K
- Arthi VenkatCharlottesville$9K
- Andrew PittnerCharlottesville$5K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.